In the current Alzheimer’s disease (AD) therapeutic space, the two approved disease-modifying therapies (DMTs) employ ...

Apellis Pharmaceuticals saw its shares leap 136% to $40.47 in pre-market activity today, on the announcement of an agreement ...

Austrian biotech Proxygen, which is pioneering the discovery of molecular glue degraders and next-generation proximity-based ...

Japan’s Tanabe Pharma Corporation has announced detailed results from the Phase III INSPIRE study of investigational oral ...

Belgian biopharma UCB has secured European Commission approval for Kygevvi (doxecitine, doxribtimine), the first authorized ...

Torqur, a subsidiary of the incubator Swiss Rockets that is advancing treatments for oncology and dermatology, has announced ...

Shares in US biotech Viridian Therapeutics slumped by 32% Monday following the company’s announcement of topline data from the elegrobart REVEAL-1 Phase III trial in patients with active thyroid eye ...

Medicines charity group MSF (Medecins Sans Frontieres/Doctors Without Borders) reported that US drugmaker Gilead Sciences has ...

Emfret Analytics, a privately-held biotech developing platelet receptor–targeting antibodies for research, diagnostic and ...

For tens of thousands of children worldwide, idiopathic nephrotic syndrome (INS), a chronic and debilitating kidney disease, ...

Israel-based Teva Pharmaceutical Industries today announced three milestones in its biosimilar portfolio, demonstrating ...

Fund and Thailand Science Research and Innovation (TSRI) have signed a Memorandum of Understanding (MOU) to strengthen their ...